John P Vasilakos

Summary

Affiliation: St. Paul
Country: USA

Publications

  1. doi The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
    John P Vasilakos
    Drug Delivery Systems Division, 3M Center, Building 260 4S 13, St Paul, MN 55144, USA
    Expert Rev Vaccines 12:809-19. 2013
  2. pmc Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells
    Venky Ramakrishna
    Celldex Therapeutics, Inc, Phillipsburg, NJ 08865, USA
    J Transl Med 5:5. 2007
  3. ncbi Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8
    Keith B Gorden
    3M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 174:1259-68. 2005
  4. pmc Comparison of human B cell activation by TLR7 and TLR9 agonists
    John A Hanten
    Department of Pharmacology, 3M Pharmaceuticals, St Paul, MN 55144, USA
    BMC Immunol 9:39. 2008
  5. doi TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN
    Jon R Inglefield
    3M Company, St Paul, MN 55144, USA
    J Interferon Cytokine Res 28:253-63. 2008
  6. ncbi Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
    Kevin S Gorski
    3M Pharmaceuticals, Department of Pharmacology, 3M Center, 270 2S 06, St Paul, MN 55144, USA
    Int Immunol 18:1115-26. 2006
  7. ncbi Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines
    Keith K B Gorden
    Department of Pharmacology, 3M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 177:8164-70. 2006
  8. ncbi Resiquimod and other immune response modifiers as vaccine adjuvants
    Mark A Tomai
    3M Drug Delivery Systems, 3M Center, 275 3E 10 St Paul, MN 55144, USA
    Expert Rev Vaccines 6:835-47. 2007
  9. ncbi The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells
    Christie L Doxsee
    Department of Pharmacology, 3 M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 171:1156-63. 2003
  10. pmc Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists
    Woubalem Birmachu
    Pharmacology, 3M Pharmaceuticals, St Paul, Minnesota, USA
    BMC Immunol 8:26. 2007

Collaborators

Detail Information

Publications14

  1. doi The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
    John P Vasilakos
    Drug Delivery Systems Division, 3M Center, Building 260 4S 13, St Paul, MN 55144, USA
    Expert Rev Vaccines 12:809-19. 2013
    ....
  2. pmc Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells
    Venky Ramakrishna
    Celldex Therapeutics, Inc, Phillipsburg, NJ 08865, USA
    J Transl Med 5:5. 2007
    ..We demonstrate that MR and TLRs contribute towards maturation and activation of DCs by a mechanism that may be driven by a combination of adjuvant and antibody vaccines that specifically deliver antigenic targets to DCs...
  3. ncbi Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8
    Keith B Gorden
    3M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 174:1259-68. 2005
    ..Thus, this study demonstrated that TLR7 and TLR8 agonists differ in their target cell selectivity and cytokine induction profile...
  4. pmc Comparison of human B cell activation by TLR7 and TLR9 agonists
    John A Hanten
    Department of Pharmacology, 3M Pharmaceuticals, St Paul, MN 55144, USA
    BMC Immunol 9:39. 2008
    ..The direct effects of TLR7 stimulation on human B cells is less understood. The objective of this study was to compare the effects of TLR7 and TLR9 stimulation on human B cell function...
  5. doi TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN
    Jon R Inglefield
    3M Company, St Paul, MN 55144, USA
    J Interferon Cytokine Res 28:253-63. 2008
    ..Thus, the results demonstrate that the TLR7 agonist 852A inhibits in vitro proliferation of some tumor cells in a pDC-dependent and IFN-alpha-dependent manner and can delay tumor growth in vivo...
  6. ncbi Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
    Kevin S Gorski
    3M Pharmaceuticals, Department of Pharmacology, 3M Center, 270 2S 06, St Paul, MN 55144, USA
    Int Immunol 18:1115-26. 2006
    ..We conclude that IRMs can modulate NK-cell function both in vitro and in vivo and that distinct indirect pathways control human NK-cell activation by TLR-7 and TLR-8 agonists...
  7. ncbi Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines
    Keith K B Gorden
    Department of Pharmacology, 3M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 177:8164-70. 2006
    ..The cross-talk between ODNs, IRMs, and TLR7 and TLR8 uncovered by this study may have practical implications in the field of microbial infections, vaccination, and tumor therapy...
  8. ncbi Resiquimod and other immune response modifiers as vaccine adjuvants
    Mark A Tomai
    3M Drug Delivery Systems, 3M Center, 275 3E 10 St Paul, MN 55144, USA
    Expert Rev Vaccines 6:835-47. 2007
    ..For injection, resiquimod or a similar compound may need to be formulated to allow for local immune activation without induction of systemic cytokines...
  9. ncbi The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells
    Christie L Doxsee
    Department of Pharmacology, 3 M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 171:1156-63. 2003
    ..Given the efficacy of TLR7 agonists as antiviral agents, the data collectively indicate that stimulation of CD8(-) DCs through TLR7 most likely plays a role in the generation of antiviral immune responses...
  10. pmc Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists
    Woubalem Birmachu
    Pharmacology, 3M Pharmaceuticals, St Paul, Minnesota, USA
    BMC Immunol 8:26. 2007
    ..To this end, we evaluated changes in global gene expression upon stimulation of 99.9% pure human pDC with the TLR7 selective agonists 3M-852A, and the TLR7/8 agonist 3M-011...
  11. ncbi First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer
    Arkadiusz Z Dudek
    University of Minnesota Cancer Center, Minneapolis, Minnesota and 3M Pharmaceuticals, St Paul, Minnesota 55455, USA
    Clin Cancer Res 13:7119-25. 2007
    ..Our goal was to define the tolerated dose, pharmacokinetics, pharmacodynamics, and immunologic effects of 852A in humans...
  12. ncbi Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides
    Keith K B Gorden
    Department of Pharmacology, 3M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 177:6584-7. 2006
    ..Cells from TLR7(-/-) and TLR9(-/-) mice responded to the IRM/polyT ODN combination, whereas MyD88(-/-) cells did not respond. In conclusion, this study demonstrates for the first time that mouse TLR8 is functional...
  13. ncbi Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats
    David M Hammerbeck
    Department of Pharmacology, 3M Pharmaceuticals, 3M Center, Building 270 3A 10, St Paul, MN 55144, USA
    Antiviral Res 73:1-11. 2007
    ..These studies indicate that TLR7/8 agonists may have prophylactic and therapeutic benefits in the treatment of respiratory viral infections, such as influenza, when administered prior to or shortly after viral inoculation...
  14. ncbi Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
    Sheila J Gibson
    Department of Pharmacology, 3M Pharmaceuticals, 3M Center, 270 2S 06, St Paul, MN 55144 1000, USA
    Cell Immunol 218:74-86. 2002
    ..These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability...